M
MiNA Therapeutics
A platform that enables the development of new medicines that restore normal function to patients’ cells
About MiNA Therapeutics
MiNA Therapeutics is a pioneering biotechnology company specializing in small activating RNA (RNAa) therapeutics. These innovative medicines harness the body's innate mechanisms to activate genes, thereby restoring or enhancing normal gene function and protein pathways in cells. MiNA's proprietary pipeline focuses on genetic medicine, aiming to address a broad spectrum of diseases. The company collaborates with leading pharmaceutical firms to expand the application of its technology across various therapeutic areas. MiNA operates in the biotechnology and pharmaceutical markets, targeting both rare and common diseases. Its business model involves developing and advancing RNAa-based therapies through clinical trials, often in partnership with other industry leaders. Revenue is generated through strategic collaborations, research partnerships, and potential future sales of approved therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- London, United Kingdom
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 64.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, RNA, Disease, Biotech and Pharma, uk is8 life sciences, Hard Tech, proteomics, DT and LS
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2022 | $185K | — | Undisclosed | — |
| LATE VCOther financing | Jul 2021 | $14M | $152M | Eli Lilly | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for MiNA Therapeutics is 1.1K monthly website visits, down 50% over the last three months. MiNA Therapeutics's team declined 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Nxera Pharma
aMoon Fund
Series B and later1 investor entered at this stage
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MiNA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MiNA Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.